Sporadic Burkitt Lymphoma Presenting with Middle Cranial Fossa Masses with Sphenoid Bony Invasion and Acute Pancreatitis in a Child [Case Report]
Acute pancreatitis in children is usually due to infection, trauma, or anatomical abnormalities and is rarely due to obstruction from malignancy. Sporadic Burkitt lymphoma (BL) is an aggressive non-Hodgkin B-cell lymphoma that usually involves the bowel or pelvis, with isolated cases presenting as acute pancreatitis. We report a case of BL in a 12-year-old male presenting as acute pancreatitis with obstructive jaundice and a right middle cranial fossa mass invading the sphenoid bone. The common bile duct in this case was dilated to 21â€‰mm in diameter on abdominal ultrasound and to 26â€‰mm on magnetic resonance cholangiopancreatography (MRCP), significantly greater than any value reported in the literature for BL. Given the rapidly progressing nature of BL, we emphasize the importance of recognizing heterogeneous presentations of this disease to improve patient survival. We also conclude that it is important to consider malignancy in a child with acute pancreatitis, particularly in the presence of obstructive jaundice or multisystem involvement. Other Presentations. This case report has no prior publications apart from the abstract being accepted to the 2020 SIOP (International Society of Pediatric Oncology) meeting and 2020 ASPHO conference (canceled due to the COVID-19 pandemic) and subsequently published as an abstract only in Pediatric Blood and Cancer. We have also presented the abstract as a poster presentation at our institution's (NYU Langone Hospital-Long Island, previously known as NYU Winthrop) annual research day conference in 2020.
Sporadic Burkitt Lymphoma Presenting With Sphenoid Bone Invasion and Acute Pancreatitis in a Child [Meeting Abstract]
NEPHROLITHIASIS IN CHRONICALLY TRANSFUSED PATIENTS SECONDARY TO DEFERASIROX USE [Meeting Abstract]
MANAGEMENT OF EARLY SEPSIS IN NEUTROPENIC PEDIATRIC ONCOLOGY PATIENTS IN AN ARTICLE 28 INSTITUTION IN THE OUTPATIENT SETTING TO OPTIMIZE PATIENT OUTCOME [Meeting Abstract]
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors
Background/UNASSIGNED:Neurofibromatosis 1 (NF1) leads to the development of benign and malignant peripheral nerve sheath tumors (MPNST). MPNST have been described to develop in preexisting benign plexiform neurofibromas (PN) and have a poor prognosis. Atypical neurofibromas (ANF) were recently described as precursor lesions for MPNST, making early detection and management of ANF a possible strategy to prevent MPNST. We aimed to clinically characterize ANF and identify management approaches. Methods/UNASSIGNED:We analyzed clinical, imaging, and pathology findings of all patients with NF1 and ANF at 3 institutions. Results/UNASSIGNED:Sixty-three patients had 76 ANF (32M/31F; median age 27.1 y). On MRI, most ANF appeared as distinct nodular lesions and were 18F-fluorodeoxyglucose (FDG) avid. Forty-six ANF were associated with pain, 19 with motor weakness, 45 were palpable or visible, and 13 had no clinical signs. Completely resected ANF (N = 57) have not recurred (median follow-up, 4.1 y; range, 0-14 y). Four ANF transformed into MPNST and 17 patients had a history of MPNST in a different location than was their ANF. Conclusions/UNASSIGNED:Growth of distinct nodular lesions, pain, and FDG-PET avidity should raise concern for ANF in NF1. Patients with ANF are at greater risk for development of MPNST. Complete resection of ANF may prevent development of MPNST.
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is particularly active in lymphomas with mutations altering the BCR subunit CD79B and MYD88. We performed a proof-of-concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R). In 18 PCNSL patients, 94% showed tumor reductions with ibrutinib alone, including patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of evaluable patients achieved complete remission with DA-TEDDi-R. Increased aspergillosis was observed with ibrutinib monotherapy and DA-TEDDi-R. Aspergillosis was linked to BTK-dependent fungal immunity in a murine model. PCNSL is highly dependent on BCR signaling, and ibrutinib appears to enhance the efficacy of chemotherapy.
NO MEAN FEAT: PREDICTING RECURRENT SPLENIC SEQUESTRATION IN PEDIATRIC SICKLE CELL PATIENTS [Meeting Abstract]
Early detection of transformation of plexiform neurofibromas to malignant peripheral nerve sheath tumors in neurofibromatosis type 1. [Meeting Abstract]
MORE THAN MEETS THE EYE: INTRAOCULAR MALT LYMPHOMA IN PEDIATRICS: A CASE REPORT [Meeting Abstract]
TRANSIENT VISUAL LOSS IN AN 11 YEAR OLD BOY WITH T CELL LYMPHOBLASTIC LYMPHOMA DURING INDUCTION PHASE OF CHEMOTHERAPY: A CASE REPORT [Meeting Abstract]